Hello! Let’s get to know each other again.

A fresh new image, yet the same unwavering初心. Starting today, Shengshi Taikе officially unveils its brand-new LOGO and VI visual identity design.

The development of any brand requires keeping pace with the times and continuously innovating and optimizing. This is especially true for innovative biopharmaceutical companies, which constantly upgrade and adjust their strategies based on industry trends, company growth, and evolving market demands—ensuring both the dynamism of their corporate image and their competitive edge. Now, let’s take another look and get to know them better:

This is the original me:

This is who I am now:

The new logo continues to carry the blue and red color scheme, with rational blue symbolizing Shengshi Taikang's approach to innovative drug development, while passionate red reflects the company's commitment to pursuing cutting-edge innovation.

The new logo design is derived from the three initial letters—CGT—of CGeneTech, the company’s English name, symbolizing the vibrant energy and boundless openness of a rising sun over the vast ocean.

We’ve changed our appearance, but our "original heart" remains unchanged! Shengshi Taikе was founded in 2010 in Suzhou Industrial Park, and under the leadership of a core executive team with decades of international experience spanning the entire lifecycle of pharmaceuticals, Always Dedicated to the research, development, and industrialization of innovative small-molecule drugs aimed at breakthrough therapies.

Over the years, the company has built a robust pipeline of innovative drugs—spanning therapeutic areas such as diabetes management, cancer treatment, and rare diseases—leveraging its integrated drug R&D technology platform and diversified business vision.

Among them, the innovative new drug phospho-sitagliptin has already entered clinical trials. III In the final stages of development, it holds promise to fill the gap in domestically produced, original DPP-4 inhibitors. Three of the cancer drugs currently in development have already entered clinical trials. FGFR/VEGFR The dual-target inhibitor CGT-6321 has entered Phase 1 clinical trials for advanced solid tumors, and the drug holds promise as a potential first-in-class therapy. CXCR4 The antagonist CGT-1881 is used for hematopoietic stem cell mobilization and is more conveniently administered orally; the next-generation ALK inhibitor CGT-9475 holds promise in addressing Two Major Clinical Challenges in Lung Cancer Treatment: Drug Resistance and Brain Metastasis 。 Additionally, the country's first generic version of teriflunomide tablets—used to treat the rare disease multiple sclerosis—has been approved for market launch.

In the future, the company will be guided by unmet clinical needs—both in China and around the world. Developing innovative drugs that are highly accessible and offer superior therapeutic efficacy to benefit patients worldwide.

New LOGO At the same time the visual system was officially launched, Shengshi Taikang's brand-new official website also went live. If you'd like to learn more about us, simply click "Read More" to be directed straight to the homepage of our website.